Brokerages Set Quest Diagnostics Incorporated (NYSE:DGX) PT at $231.73

Posted by Stanley Muller on Jul 30th, 2026

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) has been given an average recommendation of “Hold” by the thirteen analysts that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $235.3077.

DGX has been the topic of several research reports. UBS Group upped their price target on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Robert W. Baird lifted their price objective on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Truist Financial boosted their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday.

View Our Latest Report on DGX

Quest Diagnostics Stock Performance

DGX stock opened at $235.01 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The company has a 50 day moving average price of $205.78 and a 200 day moving average price of $198.92. Quest Diagnostics has a fifty-two week low of $166.75 and a fifty-two week high of $240.13. The stock has a market capitalization of $25.94 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 2.17 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts forecast that Quest Diagnostics will post 11.16 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were issued a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.5%. The ex-dividend date was Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Quest Diagnostics

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC acquired a new position in shares of Quest Diagnostics during the 4th quarter worth about $323,000. Cresset Asset Management LLC boosted its stake in Quest Diagnostics by 4.6% during the 2nd quarter. Cresset Asset Management LLC now owns 4,003 shares of the medical research company’s stock worth $719,000 after acquiring an additional 176 shares during the last quarter. Gabelli Funds LLC bought a new position in Quest Diagnostics during the 2nd quarter worth approximately $287,000. Bank of Nova Scotia grew its holdings in Quest Diagnostics by 7.2% during the second quarter. Bank of Nova Scotia now owns 14,339 shares of the medical research company’s stock valued at $2,576,000 after purchasing an additional 962 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in Quest Diagnostics by 17.1% in the second quarter. Daiwa Securities Group Inc. now owns 18,599 shares of the medical research company’s stock valued at $3,341,000 after purchasing an additional 2,718 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.